Executive David Ricks News Today

Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for cosmetic weight loss.

Order Reprints Text size Lilly is entering the field of gene editing with a deal for Prevail Therapeutics. Frederick Florin/AFP via Getty Images Sales of a Covid-battling antibody helped allow Eli Lilly to lift its sales forecast for this year and tell Wall Street to expect better results than analysts had anticipated for 2021. In a Tuesday morning business update, the drug giant (ticker: LLY) said it could earn as much as $7.65 a share this year, and $8.40 the n...